Stocks fall as uniQure, Fair Isaac, and ClearPoint Neuro lead losses on clinical and regulatory concerns.

Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market position. ClearPoint Neuro declined 23.12% despite reporting 18% revenue growth, suggesting investor caution amid valuation concerns. Other sectors like metal fabrication also saw declines, reflecting broader market weakness and risk aversion.

ClearPoint Neuro shares are trading at USD 11.84 on Pluang, down 22.66% as of Sep 30, 2026 04:11 WIB, closely matching the article's noted decline. The stock's market cap stands at $467.02 million with a 52-week range between $8.66 and $29.60. Despite the sharp drop, Pluang data shows a strong buy interest with 89% of orders being buys, indicating some investor confidence amid the volatility.